Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 16h05 HE
|
Longeveron
Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.
Longeveron Announces Board of Directors Planned Transitions
10 mai 2024 16h05 HE
|
Longeveron
Longeveron announces planned transitions on its Board of Directors.
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
02 mai 2024 08h03 HE
|
Longeveron
Longeveron to report Q1 2024 financial results on May 14, 2024.
Longeveron to Present at the Planet MicroCap Showcase
25 avr. 2024 16h05 HE
|
Longeveron
Longeveron to present at investor conference - Planet MicroCap Showcase - May 1, 2024.
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
18 avr. 2024 16h05 HE
|
Longeveron
Longeveron raises $11.4 million in gross proceeds from warrent exercise offering and public offering.
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
17 avr. 2024 08h00 HE
|
Longeveron
Longeveron raises gross proceeds of ~$6.2 M from exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its common stock.
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
15 avr. 2024 08h30 HE
|
Longeveron
Data from Longeveron's CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B in Alzheimer’s Disease has been accepted for two presentations at AAIC.
Longeveron Announces Closing of $5.2 Million Public Offering
11 avr. 2024 17h17 HE
|
Longeveron
Longeveron announces closing of previously announced public offering, raising $5.25 million in gross proceeds.
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
08 avr. 2024 08h30 HE
|
Longeveron
CEO Letter to Shareholders. Update on overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.
Investors with substantial Losses in NASDAQ: LGVN shares should contact the Shareholders Foundation in connection with the Lawsuit against Longeveron Inc.
09 nov. 2021 09h20 HE
|
Shareholders Foundation, Inc.
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Longeveron Inc. (NASDAQ: LGVN). Investors who...